Examining Longitudinal Markers of Bladder Cancer Recurrence Through a Semi-Autonomous Machine Learning System for Quantifying Specimen Atypia from Urine Cytology - Levy, Joshua J.; Chan, Natt; Marotti, Jonathan D.; Rodrigues, Nathalie J.; Ismail, A. Aziz O.; Kerr, Darcy A.; Gutmann, Edward J.; Glass, Ryan E.; Dodge, Caroline P.; Suriawinata, Arief A.; Christensen, Brock; Liu, Xiaoying; et al. (medRxiv, 2023)
Urine cytology (UC) is generally considered the primary approach for screening for recurrence of bladder cancer. However, it is currently unclear how best to use cytological exams themselves for the assessment and early detection of recurrence, beyond identifying a positive finding which requires more invasive methods to confirm recurrence and decide on therapeutic options. As screening programs are frequent, and can be burdensome, finding quantitative means to reduce this burden for patients, cytopathologists and urologists is an important endeavor and can improve both the efficiency and reliability of findings. Additionally, identifying ways to risk-stratify patients is crucial for improving quality of life while reducing the risk of future recurrence or progression of the cancer. In this study, we leveraged a computational machine learning tool, AutoParis-X, to extract imaging features from UC exams longitudinally to study the predictive potential of urine cytology for assessing recurrence risk. This study examined how the significance of imaging predictors changes over time before and after surgery to determine which predictors and time periods are most relevant for assessing recurrence risk. Results indicate that imaging predictors extracted using AutoParis-X can predict recurrence as well or better than traditional cytological / histological assessments alone and that the predictiveness of these features is variable across time, with key differences in overall specimen atypia identified immediately before tumor recurrence. Further research will clarify how computational methods can be effectively utilized in high volume screening programs to improve recurrence detection and complement traditional modes of assessment.Competing Interest StatementThe authors have declared no competing interest.Funding StatementJL is supported by NIH subawards P20GM104416 and P20GM130454Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Dartmouth Hitchcock Health IRB of Dartmouth Health gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.